16 January, 2014 - ThromboGenics NV announces today that the Transparency Commission (“Commission de la Transparence” or CT) of the French National Health Authority (“Haute Autorité de Santé” or HAS) has issued a positive opinion for the reimbursement and hospital listing of Jetrea by the French National Health Insurance.The CT recommends Jetrea for the treatment of adult patients with vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns, for whom symptomatology does not require immediately a vitrectomy at the earlier stage of this disease. Those patients represent the vast majority (85%) of the total patient population covered by the approved label from EMA in March 2013.

For more details, go to: http://www.thrombogenics.com/content/frances-transparency-commission-issues-positive-opinion-reimbursement-jetrea®